API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

Acetaldehyde: Sources and Multiple DNA repair pathways

Acetaldehyde is the primary metabolite of alcohol and is present in many environmental sources including tobacco smoke.

May 6,2024  API

ISRIB (trans-Isomer): A Promising Compound in Biochemical Research

Integrated Stress Response inhibitor ISRIB (TRANS-ISOMER)), chemically recognized as the trans-isomer.

May 6,2024  API

Unveiling (R)-DIFLUORPHOS(TM): A Catalyst for Change in Organophosphorus Chemistry

(R)-DIFLUORPHOS(TM) This specialized ligand is gaining traction in academic and industrial settings due to its unique properties and versatile applications.

May 6,2024  API

Pyridinium p-Toluenesulfonate: Versatile Catalyst Driving Efficient Synthesis in Chemical Research

Pyridinium p-toluenesulfonate is a versatile catalyst, enabling efficient synthesis of chiral compounds with high selectivity and facilitating key chemical processes.

May 6,2024  API

D-Mannose: Overview, Clinical Applications in Urinary Tract Infections and Adverse Events

D-Mannose prevents urinary tract infections by inhibiting bacterial adhesion. It's effective with minimal adverse events, mainly mild diarrhea, making it safer than nitrofurantoin.

Apr 30,2024  API

The Comprehensive Profile of 1-Dodecanethiol: Synthesis, Composition, Applications, and Toxicity

1-Dodecanethiol, often referred to as lauryl mercaptan, is an organic compound belonging to the family of alkyl thiols.

Apr 30,2024  API

Luteolin: Overview and its Anticancer Perspectives

Luteolin, a natural compound with antioxidant and anticancer properties, shows promise in inhibiting cancer progression in breast and prostate cancer through various mechanisms

Apr 30,2024  API

D-Proline: Biological Distribution and Applications in Pharmaceutical Synthesis

D-Proline, vital in pharmaceutical synthesis, aids in drug creation, especially in asymmetric synthesis and peptide-based development, advancing pharmaceutical research.

Apr 30,2024  API

Cuprous Bromide: Overview, Applications in the Synthesis of Crystal and Synthesis Method

Cuprous bromide, synthesized from copper(II) oxide and hydrobromic acid, showcases versatile properties crucial in crystal synthesis.

Apr 29,2024  API

Tildacerfont: A New Frontier in the Treatment of Hypercortisolism

One of the most promising developments in this area is Tildacerfont, a novel therapy designed to combat hypercortisolism.

Apr 29,2024  API
Prev12345678910...Next>  Go to Page